Yantai Zhenghai Biotechnology 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Kan Song

최고 경영자

CN¥1.1m

총 보상

CEO 급여 비율	n/a
CEO 임기	1.9yrs
CEO 소유권	n/a
경영진 평균 재임 기간	4.6yrs
이사회 평균 재임 기간	5.2yrs

최근 관리 업데이트

Recent updates

Yantai Zhenghai Biotechnology Co., Ltd.'s (SZSE:300653) Shares Not Telling The Full Story

Sep 28

Yantai Zhenghai Biotechnology Co., Ltd. (SZSE:300653) Held Back By Insufficient Growth Even After Shares Climb 26%

Mar 04

CEO

Kan Song (41 yo)

1.9yrs

테뉴어

CN¥1,116,100

보상

Mr. Kan Song is Chairman since April 12, 2023 & General Manager and Director of Yantai Zhenghai Biotechnology Co., Ltd. from January 06, 2023. He is Secretary of Yantai Zhenghai Biotechnology Co., Ltd sinc...

리더십 팀

이름	위치	테뉴어	보상	소유권
Kan Song	GM, Secretary & Chairman	1.9yrs	CN¥1.12m	데이터 없음
Li Zhao	Deputy GM	no data	CN¥904.90k	데이터 없음
Xing Yang	Deputy General Manager	4.6yrs	CN¥1.52m	데이터 없음
Donggang Zhang	Deputy General Manager	7.3yrs	CN¥907.90k	데이터 없음

4.6yrs

평균 재임 기간

46.5yo

평균 연령

경험이 풍부한 관리: 300653 의 관리팀은 경험 ( 4.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Kan Song	GM, Secretary & Chairman	1.8yrs	CN¥1.12m	데이터 없음
Li Zhao	Deputy GM	4.5yrs	CN¥904.90k	데이터 없음
Dong Qun	Vice Chairman	9.4yrs	데이터 없음	데이터 없음
Chao Zhang	Non-Independent Director	6.6yrs	데이터 없음	데이터 없음
Weiguo Jiang	Non-Independent Director	5.2yrs	데이터 없음	데이터 없음
Hui Xu	Independent Director	3.6yrs	CN¥60.00k	데이터 없음
Xiliang Song	Independent Director	3.6yrs	CN¥60.00k	데이터 없음
Landing Zhang	Independent Director	3.6yrs	CN¥60.00k	데이터 없음
Yueli Xu	Chairman of the Supervisory Board	9.4yrs	데이터 없음	데이터 없음
Lishan Pan	Non-Employee Supervisor	5.2yrs	데이터 없음	데이터 없음
Lei Zhao	Employee Supervisor	9.4yrs	데이터 없음	데이터 없음

5.2yrs

평균 재임 기간

49yo

평균 연령

경험이 풍부한 이사회: 300653 의 이사회는 경험(평균 재직 기간 5.2 년)으로 간주됩니다.

Yantai Zhenghai Biotechnology 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Yantai Zhenghai Biotechnology Co., Ltd., Annual General Meeting, Apr 22, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.21 in 3Q 2023)

Investor sentiment deteriorates as stock falls 19%

New major risk - Share price stability

Yantai Zhenghai Biotechnology Co., Ltd. to Report Q3, 2024 Results on Oct 23, 2024

Yantai Zhenghai Biotechnology Co., Ltd.'s (SZSE:300653) Shares Not Telling The Full Story

Investor sentiment improves as stock rises 16%

Now 22% overvalued

Now 20% overvalued

Investor sentiment deteriorates as stock falls 16%

New minor risk - Share price stability

Price target decreased by 7.6% to CN¥30.12

Second quarter 2024 earnings released: EPS: CN¥0.26 (vs CN¥0.31 in 2Q 2023)

Yantai Zhenghai Biotechnology Co., Ltd. to Report First Half, 2024 Results on Aug 06, 2024

Yantai Zhenghai Biotechnology Co., Ltd. Announces Final Dividend on A Shares for the Year 2023, Payable on 14 June 2024

Investor sentiment improves as stock rises 17%

First quarter 2024 earnings released: EPS: CN¥0.22 (vs CN¥0.30 in 1Q 2023)

Price target decreased by 10% to CN¥31.34

Yantai Zhenghai Biotechnology Co., Ltd., Annual General Meeting, Apr 22, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Yantai Zhenghai Biotechnology Co., Ltd. to Report Q1, 2024 Results on Apr 29, 2024

Yantai Zhenghai Biotechnology Co., Ltd. (SZSE:300653) Held Back By Insufficient Growth Even After Shares Climb 26%

Investor sentiment deteriorates as stock falls 17%

Yantai Zhenghai Biotechnology Co., Ltd. to Report Fiscal Year 2023 Results on Apr 02, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.28 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.31 (vs CN¥0.27 in 2Q 2022)

Yantai Zhenghai Biotechnology Co., Ltd. to Report First Half, 2023 Results on Aug 01, 2023

Yantai Zhenghai Biotechnology Co., Ltd. Implements Final Cash Dividend of 10 A Shares for 2022, Payable on May 30, 2023

Investor sentiment deteriorates as stock falls 22%

Now 29% undervalued after recent price drop

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings released: EPS: CN¥1.01 (vs CN¥0.93 in FY 2021)

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: CN¥0.28 (vs CN¥0.25 in 3Q 2021)

Investor sentiment improved over the past week

Now 26% undervalued after recent price drop

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.27 (vs CN¥0.21 in 2Q 2021)

Investor sentiment improved over the past week

Yantai Zhenghai Biotechnology Co., Ltd. Announces Final Cash Dividend for the Year 2021, Payable on May 19, 2022

High number of new and inexperienced directors

First quarter 2022 earnings: EPS exceeds analyst expectations

Yantai Zhenghai Biotechnology Co., Ltd. Proposes Distribution for 2021

Full year 2021 earnings: EPS exceeds analyst expectations

Third quarter 2021 earnings released: EPS CN¥0.37 (vs CN¥0.34 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.31 (vs CN¥0.30 in 2Q 2020)

Yantai Zhenghai Biotechnology Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2020, Payable on May 20, 2021

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.37 (vs CN¥0.16 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.99 (vs CN¥0.89 in FY 2019)

New 90-day low: CN¥45.02

New 90-day low: CN¥49.35

New 90-day low: CN¥52.20

Investor sentiment deteriorated over the past week

New 90-day low: CN¥57.91

New 90-day low: CN¥61.00

Third quarter earnings released

New 90-day low: CN¥68.30

First half earnings released

Yantai Zhenghai Biotechnology Co., Ltd. to Report First Half, 2020 Results on Aug 05, 2020

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령